Almost every peptide drug is injected, and the reason is not habit. A peptide is a chain of amino acids, and the digestive tract is built to cut such chains into single amino acids and absorb those as food. What survives the enzymes is then too large, and too water-loving, to cross the gut wall in any quantity.
A handful of peptide drugs are nonetheless approved as tablets or capsules. Each got there by a specific engineering trick, and each label prints how much of a swallowed dose actually reaches the blood. Read side by side, those labels are the most precise public answer to the question "do oral peptides work?" — and they set the bar that any oral research product would have to clear.
The approved oral peptides, and what their labels print
All figures below are from the current US labels on openFDA and the approval records on Drugs@FDA, read on 30 September 2026.
| Product (active) | Approved | How it gets around digestion | What the label says reaches the blood |
|---|---|---|---|
| RYBELSUS / OZEMPIC tablets (semaglutide) | 2019-09-20 | Co-formulated with SNAC, an absorption enhancer; absorbed mainly in the stomach | 0.4%–1% (RYBELSUS 3/7/14 mg); 1%–2% (OZEMPIC tablets 1.5/4/9 mg) |
| DDAVP tablets (desmopressin) | 1995-09-06 | A very potent nine-amino-acid peptide, so a tiny absorbed fraction is enough | about 0.16% of an intravenous dose; about 5% of the nasal spray |
| MYCAPSSA (octreotide) | 2020-06-26 | Enteric-coated capsule with a permeation-enhancing formulation | 20 mg oral ≈ 0.1 mg injected in overall exposure (200 to 1); food cuts absorption by about 90% |
| NEORAL (cyclosporine) | 1995-07-14 | A cyclic peptide of eleven amino acids, unusually resistant to digestion | Absolute bioavailability of the older SANDIMMUNE form: under 10% to as much as 89%, depending on the patient group; NEORAL's own figure not determined in adults |
| LINZESS (linaclotide) | 2012-08-30 | Not meant to be absorbed: it acts on receptors lining the gut | Plasma levels below the limit of quantitation at 72, 145 and 290 mcg |
| TRULANCE (plecanatide) | 2017-01-19 | Same design: acts inside the gut | Below the limit of quantitation in most samples at 3 mg |
The comparison that makes these figures concrete is injected semaglutide. The WEGOVY label gives its absolute bioavailability under the skin as 89%. Taken by mouth, the same molecule manages about one percent.
What "one percent" costs in milligrams
The semaglutide label contains its own conversion. A patient on the 0.5 mg weekly OZEMPIC injection may switch to RYBELSUS at 7 or 14 mg once a day. That is 49 to 98 mg swallowed each week in place of 0.5 mg injected — our arithmetic, from the label's own figures — or roughly 100 to 200 times the milligrams for a comparable treatment. The two tablet brands are, in the label's words, "not substitutable on a mg-to-mg basis", even with each other.
Octreotide gives the same lesson in a single line: the MYCAPSSA label reports that 20 mg by mouth produced overall exposure similar to 0.1 mg injected. Desmopressin tablets work at about one six-hundredth of the intravenous exposure because the molecule is potent enough that a sliver suffices.
The labels also print how fragile oral absorption is. RYBELSUS is to be taken on an empty stomach in the morning with no more than 4 ounces of plain water, swallowed whole, with a 30-minute wait before any food, drink or other oral medicine. MYCAPSSA taken with food lost about 90% of its absorption in the manufacturer's food-effect study. These are not incidental instructions; they are the conditions under which the stated bioavailability was measured.
The counter-example that is not a peptide
The newest oral weight-loss drug, orforglipron (FOUNDAYO), is often grouped with the oral peptides. It is a small molecule that activates the GLP-1 receptor, which is precisely why it can be swallowed without an absorption enhancer or fasting ritual. The trial and label milligrams, and why they differ, are on our orforglipron dosage page. GLP-1 tablets as a treatment choice are covered in depth by glp1ledger's guide to oral GLP-1 drugs.
Research-market oral peptides: what has been measured
Capsules, tablets and "oral solutions" of BPC-157 are sold widely, as are tablets of other research compounds. The record behind them is thin in a specific, checkable way:
- BPC-157. The only formal pharmacokinetic and distribution study we found (He et al., Front Pharmacol 2022, PMID 36588717) dosed rats and beagle dogs by intravenous and intramuscular injection. It measured a plasma half-life under 30 minutes, intramuscular bioavailability of about 14%–19% in rats and 45%–51% in dogs, and rapid breakdown into small fragments and single amino acids. It reported no oral bioavailability. A 2026 formulation review (Pharmaceutics, PMID 42198317) states that BPC-157 "lacks bcs classification data, permeability characterization" and that no pharmaceutical-grade formulation has been developed. Claims that it is stable in gastric juice come from animal work by its originating group, not from human absorption data. The doses sources cite, by route, are on our BPC-157 dosage page.
- SLU-PP-332. Sold as a 50 mg tablet, although it is not a peptide, and the laboratory that created it published in 2026 that it "lacks oral bioavailability". See our SLU-PP-332 dosage page and the SLU-PP-332 side-effects record.
None of this shows that an oral research peptide does nothing. It shows that nobody has published the measurement the approved products were required to make before a single tablet was sold. MuscleLedger's page on oral peptides for muscle growth covers the training-audience claims made for these products.
Collagen peptides are a different question
"Collagen peptides" sold as powders are hydrolysed protein, eaten in gram quantities and digested like any other dietary protein. They are regulated as food, not drugs. The pharmaceutical question on this page — how much of an intact, active peptide reaches the blood — is not the claim collagen products rest on, and their labels do not print a bioavailability figure for that reason.
What is not established
- A measured human oral bioavailability for any research-market peptide sold as a capsule, tablet or oral liquid.
- Whether an absorption enhancer of the kind in semaglutide tablets is present in any research-market oral product; vendor pages we have read do not state one.
- Whether the stated milligrams in a research capsule are present at all. That question belongs to testing, and our guide to reading a certificate of analysis sets out what a certificate can and cannot show.
For the injected route most of these compounds are actually used by, see our subcutaneous injection guide; for the nasal route, the peptide nasal spray record. Anyone considering an oral product with a medical purpose should take the label and the question to a prescriber.
Sources and dates
- RYBELSUS / OZEMPIC tablets (semaglutide), Novo Nordisk, NDA 213051: openFDA label effective 2026-01-30, sections 2 and 12.3. WEGOVY (semaglutide injection), NDA 215256: openFDA label, section 12.3. Read 2026-09-30.
- DDAVP tablets (desmopressin acetate), Ferring, NDA 019955: openFDA label effective 2021-02-03, clinical pharmacology.
- MYCAPSSA (octreotide) capsules, NDA 208232: openFDA label effective 2025-07-24, section 12.3.
- NEORAL (cyclosporine), NDA 050715/050716: openFDA label effective 2026-08-10, absorption section.
- LINZESS (linaclotide), NDA 202811: openFDA label effective 2026-05-21; TRULANCE (plecanatide), NDA 208745: openFDA label effective 2024-04-04; section 12.3 of each.
- Drugs@FDA original approval dates for the six applications above, via the openFDA drugsfda endpoint, 2026-09-30.
- He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol 2022;13:1026182 (PMID 36588717). Mateescu DM et al. BPC-157 as an investigational peptide therapeutic. Pharmaceutics 2026;18(5):625 (PMID 42198317). PubMed abstracts read 2026-09-30.
- Billon C et al. J Pharmacol Exp Ther 2026;393(1):103787 (PMID 41421047), for the SLU-PP-332 oral-bioavailability statement.
Corrections go to the contact page.